Reports from the 2009 London Book Fair
by London bookworm 2009
3: So what about academic publishing?
The area of academic publishing might not appear to highlight
issues of interest to a wider writing audience but these specialist journals
are being forced to respond to the digital world where faster turnaround times
and the downward pressure on prices are forcing rapid change. So the SMT
(Science, Medical & Technical) journals might be pointing a way towards the
future.
The conflict
In academic publishing the needs of the writer and the
pressures on the publisher are somewhat different. The writer is anxious to
have their work made available as quickly as possible, especially in a
fast-moving area where publication might establish certain commercial rights.
Even if it is simply a matter of pride and wanting to be the first to explain a
discovery or invention, making the work visible as quickly as possible is an
issue.
But publishers in the scientific medical and technical field
have a reputation to protect. The success of their journals depends upon
publishing relevant, credible and accurate material, so they are not in as much
of a hurry as the writer.
Another driving force behind these changes is the increasing
role of government and not-for-profit organisations as the sponsors of research.
It is often a condition of any grant of public funds that the findings should be
published and the results open to all, which adds another conflict. To get round
the clashes between these diverse interests some creative approaches have been
adopted.
There is also an increasing trend towards allowing the issue of
a licence rather than getting involved in licensing copyright.
Licensing
Because it is increasingly difficult to decide exactly who
owns which rights, journal publishers are turning to licences that specify what
the author is entitled to do with their work and also what the publisher is
allowed to do.
Once an article is accepted for publication, the publisher often
allows some pre-publication of the work. This is often circumscribed, perhaps
limiting publication to a private or institutional website.
A licence might set out what happens to any pre-published
piece when the final article is actually published. If the writer is allowed
to publish their work on their own website they might be required to remove it
and replace it with the PDF which the publisher has produced. This version
incorporates all the reviewing, editing and quality artwork which is the
hallmark of many of the journals. Most writers would of course want to remove
their initial efforts and replace them with a definitive model, but that again
has to be agreed.
Because the publisher often relies on subscriptions for their
income, the licence might call for any pre-published piece to be replaced with a
link to the publisher’s site. The writer gets the benefit of early exposure
and the publisher picks up lots of links as news of the article spreads.
The use of the embargo as one of the licensing conditions is
increasing. An embargo might prevent the work being pre-published too early and
will not allow for it to be re-published before a certain date. However,
anecdotal evidence suggests that funding bodies apply pressure to keep such
restrictions as short as possible. The conflict is between the rights of the
publisher to obtain money by restricting access against the desire of the writer
and those probably funding research to have the work made freely accessible.
The tight definition of these rights, with each stage being
specified, could provide a good model for new writers in other fields who
recognise the need to put their work about. Most academic writers will have had
to sign several amendments to existing publishing contracts over the last few
decades, and a model where the creator grants rights for certain purposes and
for specified durations has much to recommend itself, from the writer’s point of
view.
The ultimate copyright used to rest with the publishers, but
in the modern world of SMT publication the rights of the creator over their work
can be better set out in a licence. This is the case in about half of the
journals which responded to a poll run by John Cox Associates. In that same
survey it also emerged that 13% of journals did not appear to worry about
constructing a licence, with publication effectively providing open access with
publication.
Some disciplines are noticeably more conservative. The report
was rather coy in identifying these areas but we should all be relieved to
discover that the pharmaceutical and medical journals are very cautious in what
they publish and in the use of that is made of their material.
It is interesting to note that the smaller journals appear to
be more cautious and restrictive when compared with the larger organisations,
which tend to be less concerned or less prescriptive about what the writer can
do with their work pre- and post-publication. But they do like to define the
timetable.
© Chas Jones 2009